RxDoctor Payments Data

Elizabeth Blachly, MD

Family Medicine · New Palestine, INNPI 1740282201

Payments from drug & device makers

$1,365in general payments, 2019–2025

Across 89 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$219
  • Novo Nordisk$187
  • Lilly USA, LLC$165
  • AstraZeneca$147
  • Boehringer Ingelheim$127
  • AbbVie$59
  • plus $461 from 14 others

What the payments were for

  • Food & beverage$1,17786%
  • Education$18814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,365 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$124,299
Medicare patients
136
Services billed
2,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$47,229
JardianceEmpagliflozin30$41,585
RybelsusSemaglutide26$30,093
MounjaroTirzepatide16$28,729
OzempicSemaglutide22$28,374
XareltoRivaroxaban17$21,169
Spiriva RespimatTiotropium Bromide29$20,541
MyrbetriqMirabegron21$19,771
Mirabegron ErMirabegron14$13,100
Tresiba Flextouch U-100Insulin Degludec16$8,039
Celecoxib51$6,260
SymbicortBudesonide/Formoterol Fumarate20$6,068
ShingrixVaricella-Zoster Ge/As01b/Pf27$5,906
VyvanseLisdexamfetamine Dimesylate15$5,794
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$127$62,12659 claims
Novo NordiskRybelsus, Ozempic$187$58,46748 claims
PfizerEliquis, Abrysvo$56$51,04250 claims
Lilly USA, LLCMounjaro$165$28,72916 claims
Johnson & JohnsonXarelto$23$21,16917 claims
Astellas Pharma US IncMyrbetriq$219$19,77121 claims
AstraZenecaSymbicort$147$6,06820 claims
AbbVieSynthroid$59$1,93224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in New Palestine

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →